Effect of single intralesional treatment of surgically induced equine superficial digital flexor tendon core lesions with adipose-derived mesenchymal stromal cells: a controlled experimental trial.
Effect of single intralesional treatment of surgically induced equine superficial digital flexor tendon core lesions with adipose-derived mesenchymal stromal cells: a controlled experimental trial.
复制标题
DOI：
10.1186/s13287-017-0564-8
复制
发表时间：
2017-06-05
影响因子：
7.5
通讯作者：
Stadler PM
中科院分区：
文献类型：
--
作者：
Geburek F;Roggel F;van Schie HTM;Beineke A;Estrada R;Weber K;Hellige M;Rohn K;Jagodzinski M;Welke B;Hurschler C;Conrad S;Skutella T;van de Lest C;van Weeren R;Stadler PM
脂肪组织是用于治疗肌腱疾病的间充质基质细胞（MSC）的有前途的来源。本研究的目的是评估单次病灶内植入脂肪组织来源的间充质基质细胞（AT-MSC）对马浅屈肌腱（SDFT）人工损伤的影响。在这项随机、对照、盲法实验研究中，在 9 匹马的双前肢手术产生位于中央的 SDFT 病灶后 2 周，将悬浮在自体灭活血清（AT-MSC-血清）中的自体培养 AT-MSC 或自体灭活血清（血清）注射到病灶内。在 24 周内定期对愈合情况进行临床评估和超声检查（标准 B 型和超声组织表征）。对马实施安乐死后，对 SDFT 进行组织学、生物化学和生物力学测试。 AT-MSC 植入对临床和超声检查参数没有显着影响。 24 周后，修复组织的组织学、生化和生物力学特征在不同治疗方式之间没有显着差异。与宏观正常肌腱组织相比，AT-MSC血清治疗后成熟胶原交联羟赖氨吡啶啉的含量没有差异（p = 0.074），而仅用血清治疗的病变中其含量显着降低（p = 0.027）。 AT-MSC血清治疗后的失效应力（p = 0.048）和弹性模量（p = 0.001）显着低于正常肌腱组织。在 22 周的观察期内，在肌腱病手术模型中，单次病灶内注射悬浮于自体灭活血清中的培养 AT-MSC 的效果并不优于仅使用自体灭活血清手术产生的 SDFT 病灶。 AT-MSC 治疗可能对重塑疤痕组织的胶原交联产生积极影响。需要进行包括自然发生的肌腱病在内的受控长期研究来验证 AT-MSC 对肌腱疾病的影响。本文的在线版本 (doi:10.1186/s13287-017-0564-8) 包含补充材料，可供授权用户使用。
Adipose tissue is a promising source of mesenchymal stromal cells (MSCs) for the treatment of tendon disease. The goal of this study was to assess the effect of a single intralesional implantation of adipose tissue-derived mesenchymal stromal cells (AT-MSCs) on artificial lesions in equine superficial digital flexor tendons (SDFTs). During this randomized, controlled, blinded experimental study, either autologous cultured AT-MSCs suspended in autologous inactivated serum (AT-MSC-serum) or autologous inactivated serum (serum) were injected intralesionally 2 weeks after surgical creation of centrally located SDFT lesions in both forelimbs of nine horses. Healing was assessed clinically and with ultrasound (standard B-mode and ultrasound tissue characterization) at regular intervals over 24 weeks. After euthanasia of the horses the SDFTs were examined histologically, biochemically and by means of biomechanical testing. AT-MSC implantation did not substantially influence clinical and ultrasonographic parameters. Histology, biochemical and biomechanical characteristics of the repair tissue did not differ significantly between treatment modalities after 24 weeks. Compared with macroscopically normal tendon tissue, the content of the mature collagen crosslink hydroxylysylpyridinoline did not differ after AT-MSC-serum treatment (p = 0.074) while it was significantly lower (p = 0.027) in lesions treated with serum alone. Stress at failure (p = 0.048) and the modulus of elasticity (p = 0.001) were significantly lower after AT-MSC-serum treatment than in normal tendon tissue. The effect of a single intralesional injection of cultured AT-MSCs suspended in autologous inactivated serum was not superior to treatment of surgically created SDFT lesions with autologous inactivated serum alone in a surgical model of tendinopathy over an observation period of 22 weeks. AT-MSC treatment might have a positive influence on collagen crosslinking of remodelling scar tissue. Controlled long-term studies including naturally occurring tendinopathies are necessary to verify the effects of AT-MSCs on tendon disease. The online version of this article (doi:10.1186/s13287-017-0564-8) contains supplementary material, which is available to authorized users.